{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:55:46Z","timestamp":1775040946427,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003037","name":"Elan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003037","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ortho-McNeill"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","award":["PG002141"],"award-info":[{"award-number":["PG002141"]}],"id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","award":["IN002264"],"award-info":[{"award-number":["IN002264"]}],"id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.seizure.2018.09.014","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T12:33:21Z","timestamp":1537619601000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-5518","authenticated-orcid":false,"given":"Baibing","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunmi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Legge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil","family":"Detyniecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2018.09.014_bib0005","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1212\/01.wnl.0000247045.85646.c0","article-title":"Psychotropic effects of antiepileptic drugs","volume":"67","author":"Ettinger","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"Suppl 2","key":"10.1016\/j.seizure.2018.09.014_bib0015","first-page":"S42","article-title":"Adverse effects of antiepileptic drugs","volume":"41","author":"Greenwood","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","article-title":"Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations","volume":"26","author":"Piedad","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2018.09.014_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00002018-200730020-00003","article-title":"Suicidality and antiepileptic drugs: is there a link?","volume":"30","author":"Kalinin","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2018.09.014_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/epd.2009.0238","article-title":"Antiepileptic drugs and psychopathology of epilepsy: an update","volume":"11","author":"Mula","year":"2009","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2018.09.014_bib0035","first-page":"138","article-title":"Behavioral and cognitive effects of anti-epileptic drugs","volume":"9","author":"Cavanna","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.seizure.2018.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2018.09.014_bib0050","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0055","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0060","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4065\/78.6.781","article-title":"Neuropsychiatric and memory issues in epilepsy","volume":"78","author":"Bortz","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.seizure.2018.09.014_bib0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrneurol.2012.184","article-title":"Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling","volume":"8","author":"Wood","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.seizure.2018.09.014_bib0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1535-7511.2005.00056.x","article-title":"Psychotropic effects of antiepileptic drugs","volume":"5","author":"Nadkarni","year":"2005","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2018.09.014_bib0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yebeh.2015.03.020","article-title":"Cross-sensitivity of patient-perceived adverse cognitive effects with antiepileptic drug use","volume":"46","author":"Chen","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0080","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0317167100021880","article-title":"Cross sensitivity of skin rashes with antiepileptic drugs","volume":"24","author":"Hyson","year":"1997","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.seizure.2018.09.014_bib0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/postgradmedj\/79.938.703","article-title":"Phenytoin and carbamazepine cross reactivity: report of a case and review of literature","volume":"79","author":"Misra","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.seizure.2018.09.014_bib0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/106002808902300308","article-title":"Phenytoin-carbamazepine cross-sensitivity","volume":"23","author":"Reents","year":"1989","journal-title":"DICP"},{"key":"10.1016\/j.seizure.2018.09.014_bib0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1157.1993.tb02392.x","article-title":"Cross-reactive skin eruption with both carbamazepine and oxcarbazepine","volume":"34","author":"Beran","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0190-9622(97)70292-5","article-title":"Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity","volume":"36","author":"Chan","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.seizure.2018.09.014_bib0110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2018.09.014_bib0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1059-1311(97)80060-X","article-title":"Factors influencing compliance with antiepileptic drug regimes","volume":"6","author":"Buck","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.09.014_bib0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","article-title":"Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases","volume":"4","author":"Dinkelacker","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0140","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","article-title":"Discontinuation of levetiracetam because of behavioral side effects: a case-control study","volume":"61","author":"White","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.09.014_bib0150","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00002018-200528100-00004","article-title":"Benefit-risk assessment of levetiracetam in the treatment of partial seizures","volume":"28","author":"Abou-Khalil","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.seizure.2018.09.014_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0160","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002564","article-title":"Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register","volume":"3","author":"Wieshmann","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.seizure.2018.09.014_bib0170","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2013.0599","article-title":"The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre","volume":"15","author":"Kang","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2018.09.014_bib0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1212\/WNL.0b013e3181eccfb5","article-title":"Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study","volume":"75","author":"White","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2018.09.014_bib0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/seiz.1999.0368","article-title":"Psychotic episodes during zonisamide treatment","volume":"9","author":"Miyamoto","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2018.09.014_bib0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/NDT.S4063","article-title":"Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature","volume":"5","author":"Zaccara","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2018.09.014_bib0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.yebeh.2013.08.024","article-title":"Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities","volume":"29","author":"Cavanna","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2018.09.014_bib0195","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/acps.12343","article-title":"Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis","volume":"130","author":"Taylor","year":"2014","journal-title":"Acta Psychiatr Scand"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118304953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118304953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:50:56Z","timestamp":1761011456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118304953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":39,"alternative-id":["S1059131118304953"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2018.09.014","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2018.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}